Remember when all anyone talked about was the high cost of “specialty” drugs?
The Return Of The “Specialty” Drug Pricing Debate In The US
Pharma has been almost wholly successful in shifting the ground in the US drug pricing debate away from high-cost “specialty” products and towards the large gap between list and net prices, with the most intense focus on older medicines like insulin. What happens when the debate shifts back?
